Descartes-08 for Children, Adolescents and Young Adults With Childhood-onset Systemic Lupus Erythematosus, ANCA-associated Vasculitis, Juvenile Myasthenia Gravis, and Juvenile Dermatomyositis
Status: Recruiting
Location: See all (2) locations...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 1/Phase 2
SUMMARY
Safety, tolerability and efficacy of Descarte-08 in children, adolescents and young adults with childhood-onset systemic lupus erythematosus, ANCA-associated vasculitis, juvenile myasthenia gravis, and juvenile dermatomyositis
Eligibility
Participation Requirements
Sex: All
Minimum Age: 12
Healthy Volunteers: f
View:
• At least age 12
• definitive diagnosis of childhood-onset systemic lupus erythematous, juvenile Myasthenie gravis, juvenile dermatomyositis and AAV
• Signs and symptoms of moderate disease
• History of systemic treatment
• Parent/Guardian/Patient must be able to give written informed consent
Locations
United States
Washington, D.c.
H01- Children's National Hospital
RECRUITING
Washington D.c.
Missouri
H03- Washington University School of Medicine
RECRUITING
St Louis
Contact Information
Primary
Cartesian Clinical Trials
trials@cartesiantx.com
617-231-8102
Time Frame
Start Date: 2026-01-14
Estimated Completion Date: 2028-12
Participants
Target number of participants: 50
Treatments
Experimental: Part 1: Decartes-08 to establish Maximum tolerated dose
Intra-patient dose escalation arm with three dose levels over the course of six infusions of cell product.
Experimental: Part 2: Decartes-08 infusions once weekly for 6 weeks
Descartes-08 infusions at the maximum tolerated dose level from Part 1.
Related Therapeutic Areas
Sponsors
Leads: Cartesian Therapeutics